Price Alert: Shares of Psychemedics (PMD) Trade 2.60% Higher at Midday May 13
Equities Staff Follow |Psychemedics Corp. (NASDAQ: PMD) shares moved 2.60%, or $0.163 per share, as on 11:19:12 est today. Opening the day at $6.32, 529 shares of Psychemedics have exchanged hands and the stock has moved between $6.43 and $6.32.
Already this year the company has moved YTD 10.68%.
Psychemedics expects its next earnings on 2022-08-09.
For technical charts, analysis, and more on Psychemedics visit the company profile.
About Psychemedics Corp.
Psychemedics Corporation is the world’s largest provider of hair testing for the detection of drugs of abuse. The Company’s patented process is used by thousands of U.S. and international clients, including over 10% of the Fortune 500 companies, for pre-employment and random drug testing. Major police departments, Federal Reserve Banks, schools, and other public entities also rely on company's unique patented drug testing process. Psychemedics Corporation strongly believes its drug testing method to be superior to any other product currently in use, including traditional urine testing and other hair testing methods.
To get more information on Psychemedics Corp. and to follow the company's latest updates, you can visit the company's profile page here: Psychemedics Corp.'s Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.
Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.
Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer